Advisor Group Holdings, Inc. Adaptimmune Therapeutics PLC Transaction History

Advisor Group Holdings, Inc.

  • $39.8 Billion
  • Q4 2024

A detailed history of Advisor Group Holdings, Inc. transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 15,258 shares of ADAP stock, worth $8,544. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,258
Previous 15,258 -0.0%
Holding current value
$8,544
Previous $14,000 42.86%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$0.83 - $1.47 $3,320 - $5,880
-4,000 Reduced 20.77%
15,258 $14,000
Q1 2024

May 10, 2024
BUY
$0.7 - $1.75 $9,100 - $22,750
13,000 Added 207.73%
19,258 $30,000
Q4 2023

Feb 12, 2024
SELL
$0.43 - $0.79 $1,806 - $3,318
-4,200 Reduced 40.16%
6,258 $4,000
Q3 2023

Nov 13, 2023
BUY
$0.73 - $1.04 $5,986 - $8,528
8,200 Added 363.15%
10,458 $8,000
Q2 2023

Aug 10, 2023
BUY
$0.9 - $1.51 $952 - $1,597
1,058 Added 88.17%
2,258 $2,000
Q4 2022

Feb 10, 2023
SELL
$1.05 - $2.53 $52 - $126
-50 Reduced 4.0%
1,200 $1,000
Q1 2022

May 04, 2022
BUY
$1.73 - $4.06 $346 - $811
200 Added 19.05%
1,250 $2,000
Q3 2021

Nov 05, 2021
BUY
$3.44 - $6.37 $3,440 - $6,370
1,000 Added 2000.0%
1,050 $5,000
Q2 2021

Aug 02, 2021
BUY
$3.86 - $5.78 $193 - $289
50 New
50 $0
Q4 2020

Feb 10, 2021
SELL
$4.0 - $9.2 $50,704 - $116,619
-12,676 Closed
0 $0
Q3 2020

Nov 12, 2020
BUY
$7.66 - $10.78 $97,098 - $136,647
12,676 New
12,676 $101,000
Q2 2020

Aug 14, 2020
SELL
$2.58 - $12.1 $2,580 - $12,100
-1,000 Closed
0 $0
Q1 2020

May 18, 2020
BUY
$1.2 - $4.52 $1,200 - $4,520
1,000 New
1,000 $3,000

Others Institutions Holding ADAP

# of Institutions
83
Shares Held
123M
Call Options Held
34.2K
Put Options Held
16.3K
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $91.5M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email